
OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

